⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10750623 | 1.00 | — | — | |
| SCHEMBL30142081 | 0.88 | ADH1C (0.38) | — | |
| SCHEMBL8907356 | 0.84 | PIK3CD (0.31) | — | |
| SCHEMBL8458686 | 0.84 | PIK3CD (0.31) | — | |
| SCHEMBL29832906 | 0.83 | CHRM1 (0.43) | — | |
| SCHEMBL8891955 | 0.77 | PDE4D (0.32) | — | |
| SCHEMBL6380375 | 0.76 | — | — | |
| SCHEMBL3821465 | 0.74 | ACACB (0.32) | — | |
| SCHEMBL7453924 | 0.74 | ACACB (0.32) | — | |
| SCHEMBL1487468 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408837-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139859-A | Benzimidazole and azabenzimidazole IL-17 inhibitor compounds | 詹森药业有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118119613-A | Benzimidazoles as IL-17 modulators | 詹森药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049885-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |